Kim R. Tsuchimoto
CIK: 0001333516
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Monopar Therapeutics
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Aug 26, 2026MNPR
Monopar Therapeutics
Sale(S)Direct602 shares at avg. $112.93$68K - Aug 26, 2026MNPR
Monopar Therapeutics
Sale(S)Direct590 shares at avg. $113.84$67K - Aug 26, 2026MNPR
Monopar Therapeutics
Exercise(M)Direct2.1K shares at avg. $30.00$62K - Aug 26, 2026MNPR
Monopar Therapeutics
Exercise(M)Direct2K shares at avg. $14.00$28K - Aug 26, 2026MNPR
Monopar Therapeutics
Sale(S)Direct485 shares at avg. $108.83$53K - Aug 26, 2026MNPR
Monopar Therapeutics
Sale(S)Direct615 shares at avg. $109.56$67K - Aug 26, 2026MNPR
Monopar Therapeutics
Sale(S)Direct700 shares at avg. $110.65$77K - Aug 26, 2026MNPR
Monopar Therapeutics
Sale(S)Direct1.1K shares at avg. $111.84$123K - Dec 2, 2025MNPR
Monopar Therapeutics
Award(A)DirectStock Options
2.9K shares- - Jul 14, 2025MNPR
Monopar Therapeutics
In-the-Money(X)Direct8.9K shares at avg. $0.01$44.52 - Jul 14, 2025MNPR
Monopar Therapeutics
Sale(S)Direct8.9K shares at avg. $40.00$356K - Mar 4, 2025MNPR
Monopar Therapeutics
Award(A)DirectStock Options
11.4K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 26, 2026 | MNPR Monopar Therapeutics | Sale(S) | 602 | $112.93 | $67,984 | Direct |
| Aug 26, 2026 | MNPR Monopar Therapeutics | Sale(S) | 590 | $113.84 | $67,166 | Direct |
| Aug 26, 2026 | MNPR Monopar Therapeutics | Exercise(M) | 2,055 | $30.00 | $61,650 | Direct |
| Aug 26, 2026 | MNPR Monopar Therapeutics | Exercise(M) | 2,035 | $14.00 | $28,490 | Direct |
| Aug 26, 2026 | MNPR Monopar Therapeutics | Sale(S) | 485 | $108.83 | $52,783 | Direct |
| Aug 26, 2026 | MNPR Monopar Therapeutics | Sale(S) | 615 | $109.56 | $67,379 | Direct |
| Aug 26, 2026 | MNPR Monopar Therapeutics | Sale(S) | 700 | $110.65 | $77,455 | Direct |
| Aug 26, 2026 | MNPR Monopar Therapeutics | Sale(S) | 1,098 | $111.84 | $122,800 | Direct |
| Dec 2, 2025 | MNPR Monopar Therapeutics | Award(A) Stock Options | 2,924 | - | - | Direct |
| Jul 14, 2025 | MNPR Monopar Therapeutics | In-the-Money(X) | 8,904 | $0.01 | $45 | Direct |
| Jul 14, 2025 | MNPR Monopar Therapeutics | Sale(S) | 8,904 | $40.00 | $356,171 | Direct |
| Mar 4, 2025 | MNPR Monopar Therapeutics | Award(A) Stock Options | 11,365 | - | - | Direct |
1-12 of 12 transactions
About Tsuchimoto Kim R
Tsuchimoto Kim R (SEC CIK 0001333516) files insider reports with the SEC as Director of Monopar Therapeutics (MNPR).
Signal8 holds 5 ownership filings by Tsuchimoto Kim R, all Form 4s, filed between Mar 7, 2025 and Aug 28, 2026. Those filings report 12 transactions, from Mar 4, 2025 to Aug 26, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Tsuchimoto Kim R's filings is in WILMETTE, IL.
Recent filings by Tsuchimoto Kim R
- Aug 26, 2026: Open-market sales of MNPR shares (2 lines, Form 4, code S).
- Aug 26, 2026: Option exercises of MNPR shares (2 lines, Form 4, code M).
- Aug 26, 2026: Open-market sales of MNPR shares (4 lines, Form 4, code S).
- Dec 2, 2025: Grant or award of MNPR derivative securities (Form 4, code A).
- Jul 14, 2025: Option exercise of MNPR shares (Form 4, code X).
Other insiders filing for Monopar Therapeutics (MNPR)
- Robinson Chandler, Chief Executive Officer
- STARR CHRISTOPHER M, Director
- Cittadine Andrew, Chief Operating Officer
- Vu Quan Anh, Chief Financial Officer
- Anderson Raymond, Director
- RIOUX PATRICE, Officer